Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?
View / Open Files
Authors
Publication Date
2021-04Journal Title
J Rheumatol
ISSN
0315-162X
Publisher
The Journal of Rheumatology
Volume
48
Issue
4
Pages
479-481
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Jayne, D. (2021). Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?. J Rheumatol, 48 (4), 479-481. https://doi.org/10.3899/jrheum.201351
Abstract
The management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has come a long way from the first postmortem descriptions of the diseases in the 1930s and 1950s1 Pivotal phases have been the introduction of glucocorticoids (GC) and cyclophosphamide (CYC), the association with ANCA in the 1980s, and consensus classification and nomenclature systems from 1990 onwards2.
Keywords
Humans, Antibodies, Antineutrophil Cytoplasmic, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Identifiers
External DOI: https://doi.org/10.3899/jrheum.201351
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330740
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk